REFERENCES
  1. McCormick et al. A Case of a Central Conducting Lymphatic Anomaly Responsive to Sirolimus. Pediatrics . 2016;137(1):e20152694 - April 01, 2016
  2. Lopez-Gutierrez JC, Tovar JA. Chylothorax and chylous ascites: Management and pitfalls. Seminars in Pediatric Surgery . 2014;23(5):298-302.
  3. Tutor JD. Chylothorax in Infants and Children. Pediatrics . 2014;133(4):722-733.
  4. Soto-Martinez M, Massie J. Chylothorax: Diagnosis and Management in Children. Paediatric Respiratory Reviews. 2009;10(4):199-207.
  5. Light RW. Chylothorax and pseudochylothorax. In: Pleural Diseases , 6th ed. Philadelphia, PA:Wolters Kluwer Lippincott Williams and Wilkins; 2013
  6. Beghetti M, La Scala G, Belli D, Bugmann P, Kalangos A, Le Coultre C. Etiology and management of pediatric chylothorax. J Pediatr . 2000;136(5):653–658 pmid:10802499
  7. Shah D, Sinn JK. Octreotide as therapeutic option for congenital idiopathic chylothorax: a case series. Acta Paediatr . 2012;101(4):e151–e155 pmid:22092874
  8. Roehr CC, Jung A, Proquitté H, et al. Somatostatin or octreotide as treatment options for chylothorax in young children: a systematic review. Intensive Care Med . 2006;32(5):650–657pmid:16532329
  9. Church JT, Antunez AG, Dean A, et al. Evidence-based management of chylothorax in infants. Journal of Pediatric Surgery . 2017;52(6):907-912.
  10. Das A, Shah PS. Octreotide for the treatment of chylothorax in neonates. Cochrane Database Syst Rev.  2010; (9):CD006388 pmid:20824848
  11. Wiegand S, Wichmann G, Dietz A. Treatment of Lymphatic Malformations with the mTOR Inhibitor Sirolimus: A Systematic Review. Lymphatic Research and Biology . 2018;16(4):330-339.
  12. Inoki K, Corradetti MN, Guan KL. Dysregulation of the TSC-mTOR pathway in human disease. Nat Genet. 2005;37(1):19–24pmid:15624019
  13. Adams DM, Trenor CC, Hammill AM, et al. Efficacy and Safety of Sirolimus in the Treatment of Complicated Vascular Anomalies. Pediatrics. 2016;137(2).
  14. Hammill AM, Wentzel M, Gupta A, Nelson S, Lucky A, Elleru R, et al. Sirolimus for the treatment of complicated vascular anomalies in children. Pediatr Blood Cancer 2011; 57:1018-24.
  15. McCormack FX, Inoue Y, Moss J, Singer LG, Strange C, Naka K, et al. Efficacy and safety of sirolimus in lymphangioleiomyomatosis. N Engl J Med 2011;364:1596-1606.
  16. McCormick et al. A Case of a Central Conducting Lymphatic Anomaly Responsive to Sirolimus. Pediatrics. 2016;137(1):e20152694. Pediatrics . 2016;137(4).
  17. Chen W, Adams D, Patel M, Gupta A, Dasgupta R. Generalized lymphatic malformation with chylothorax: Long-term management of a highly morbid condition in a pediatric patient. Journal of Pediatric Surgery . 2013;48(3).
  18. Ricci KW, Hammill AM, Mobberley-Schuman P, et al. Efficacy of systemic sirolimus in the treatment of generalized lymphatic anomaly and Gorham-Stout disease. Pediatric Blood & Cancer . 2019.
  19. Hodges MM, Crombleholme TM, Meyers M, et al. Massive fetal chylothorax successfully treated with postnatal talc pleurodesis: A case report and review of the literature. Journal of Pediatric Surgery Case Reports . 2016;9:1-4.